Outlook Therapeutics (OTLK) Capital Leases: 2015-2020
Historic Capital Leases for Outlook Therapeutics (OTLK) over the last 4 years, with Jun 2020 value amounting to $49,162.
- Outlook Therapeutics' Capital Leases fell 98.53% to $49,162 in Q2 2020 from the same period last year, while for Jun 2020 it was $49,162, marking a year-over-year decrease of 98.53%. This contributed to the annual value of $3.4 million for FY2019, which is 2.53% down from last year.
- Outlook Therapeutics' Capital Leases amounted to $49,162 in Q2 2020, which was down 98.53% from $3.3 million recorded in Q1 2020.
- Outlook Therapeutics' Capital Leases' 5-year high stood at $3.5 million during Q1 2018, with a 5-year trough of $28,067 in Q3 2017.
- Moreover, its 3-year median value for Capital Leases was $3.4 million (2019), whereas its average is $3.1 million.
- Per our database at Business Quant, Outlook Therapeutics' Capital Leases spiked by 12,203.62% in 2018 and then slumped by 98.53% in 2020.
- Outlook Therapeutics' Capital Leases (Quarterly) stood at $113,082 in 2016, then plummeted by 62.43% to $42,481 in 2017, then skyrocketed by 7,903.87% to $3.4 million in 2018, then decreased by 1.64% to $3.3 million in 2019, then crashed by 98.53% to $49,162 in 2020.
- Its last three reported values are $49,162 in Q2 2020, $3.3 million for Q1 2020, and $3.3 million during Q4 2019.